VS-6063

OBJECTIVES KRAS mutations, which occur in approximately 25% of lung adenocarcinoma cases, represent a major unmet clinical need… Expand

Docetaxel, the standard chemotherapy for metastatic castration‐resistant prostate cancer (CRPC) also enhances the survival of… Expand

ABSTRACT The non-receptor cytoplasmic tyrosine kinase, Focal Adhesion Kinase (FAK) is known to play a key role in a variety of… Expand

Because cancer stem cells (CSCs) have been implicated in chemo-resistance, metastasis and tumor recurrence, therapeutic targeting… Expand

AbstractPurpose VS-6063 (also known as defactinib or PF-04554878) is a second-generation inhibitor of focal adhesion kinase and… Expand

SummaryObjective VS-6063 (also known as defactinib or PF-04554878) is a second-generation inhibitor of focal adhesion kinase (FAK… Expand

Malignant pleural mesothelioma (MPM) is an aggressive tumor in the lining of the lung often resulting from prior exposure to… Expand

5521 Background: Defactinib (VS-6063) is an oral inhibitor of focal adhesion kinase (FAK). Blockade of FAK has been shown to… Expand

BACKGROUND We previously found focal adhesion kinase (FAK) inhibition sensitizes ovarian cancer to taxanes; however, the… Expand

Background: Defactinib (VS-6063) is a potent, reversible, oral inhibitor of focal adhesion kinase (FAK). Blockade of FAK reduces… Expand